来自MSN21 小时
Healx doses first subject in Phase II neurofibromatosis type 1 therapy trial
Healx has dosed the first subject in the open-label Phase II INSPIRE-NF1 trial to assess the efficacy and safety of HLX-1502 ...
GEN17 小时
Healx Candidate, SpringWorks Therapy Expand NF1 Treatment Options
Healx has dosed the first patient in a Phase II trial assessing its lead pipeline candidate HLX-1502 in patients with neurofibromatosis type 1 (NF1), while the FDA approved SpringWorks Therapeutics’ ...